[go: up one dir, main page]

IL131796A0 - Zinc free insulin crystals for use in pulmonary compositions - Google Patents

Zinc free insulin crystals for use in pulmonary compositions

Info

Publication number
IL131796A0
IL131796A0 IL13179698A IL13179698A IL131796A0 IL 131796 A0 IL131796 A0 IL 131796A0 IL 13179698 A IL13179698 A IL 13179698A IL 13179698 A IL13179698 A IL 13179698A IL 131796 A0 IL131796 A0 IL 131796A0
Authority
IL
Israel
Prior art keywords
free insulin
zinc free
insulin crystals
crystals
pulmonary compositions
Prior art date
Application number
IL13179698A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL131796A0 publication Critical patent/IL131796A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL13179698A 1997-03-20 1998-03-20 Zinc free insulin crystals for use in pulmonary compositions IL131796A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK31797 1997-03-20
PCT/DK1998/000109 WO1998042749A1 (fr) 1997-03-20 1998-03-20 Cristaux d'insuline depourvus de zinc et utiles dans des compositions pour les voies respiratoires

Publications (1)

Publication Number Publication Date
IL131796A0 true IL131796A0 (en) 2001-03-19

Family

ID=8092195

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13179698A IL131796A0 (en) 1997-03-20 1998-03-20 Zinc free insulin crystals for use in pulmonary compositions

Country Status (17)

Country Link
US (2) US20070093411A1 (fr)
EP (2) EP1005490B1 (fr)
JP (1) JP3764174B2 (fr)
KR (1) KR20000076419A (fr)
CN (1) CN1259142A (fr)
AT (1) ATE321783T1 (fr)
AU (1) AU742591B2 (fr)
BR (1) BR9808285A (fr)
CA (1) CA2283705A1 (fr)
DE (1) DE69834028T2 (fr)
ES (1) ES2260832T3 (fr)
HU (1) HUP0000547A3 (fr)
IL (1) IL131796A0 (fr)
NO (1) NO994520L (fr)
PL (1) PL335777A1 (fr)
RU (1) RU2198181C2 (fr)
WO (1) WO1998042749A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500933B1 (en) 1997-09-05 2002-12-31 Altus Biologics Inc. Methods of preparing carbohydrate crosslinked glycoprotein crystals
AU8772498A (en) 1997-09-05 1999-03-29 Altus Biologics Inc. Carbohydrate crosslinked glycoprotein crystals
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
WO1999055310A1 (fr) * 1998-04-27 1999-11-04 Altus Biologics Inc. Cristaux de proteines stabilisees, formulations renfermant lesdits cristaux et leurs procedes de fabrication
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
AU757991B2 (en) * 1998-04-27 2003-03-13 Altus Pharmaceuticals, Inc. Stabilized protein crystals, formulations containing them and methods of making them
DE19903125B4 (de) * 1999-01-27 2006-01-05 Sanofi-Aventis Deutschland Gmbh Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga
AU4450700A (en) * 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
DE10250297A1 (de) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
BRPI0413276B8 (pt) * 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
CA2553392A1 (fr) 2004-01-16 2005-08-11 Biodel Inc Dispositif d'administration sublinguale de medicaments
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
KR100798333B1 (ko) * 2005-08-03 2008-01-28 고려대학교 산학협력단 락토오스 운반체와 혼합건조된 폐 전달용 인슐린미세결정분말
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP6169354B2 (ja) * 2009-08-11 2017-07-26 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ クロマトグラフィーの方法およびその精製化合物
WO2011058082A1 (fr) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Composition pharmaceutique comprenant un agoniste de glp-1 et de la méthionine
HUE038147T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
WO2012028172A1 (fr) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Utilisation de lixisenatide pour fabrication de médicament pour traitement du diabète sucré de type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US10258573B2 (en) 2014-07-08 2019-04-16 Amphastar Pharmaceuticals, Inc. Micronized insulin and micronized insulin analogues prepared under acidic conditions, and methods of manufacturing the same under acidic conditions
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN108368163A (zh) 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
US20190010206A1 (en) 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
US10322168B2 (en) * 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
CN106749616B (zh) * 2016-12-19 2021-09-03 华润昂德生物药业有限公司 B30位苏氨酸缺失人胰岛素晶体的制备方法
CN109957001B (zh) * 2017-12-26 2022-11-18 甘李药业股份有限公司 甘赖脯胰岛素结晶的制备方法
PL238016B1 (pl) * 2018-07-06 2021-06-28 Bioton Spolka Akcyjna Krystaliczna, bezcynkowa postać insuliny glargine i sposób jej otrzymywania
WO2021116292A1 (fr) 2019-12-11 2021-06-17 Novo Nordisk A/S Nouveaux analogues de l'insuline et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE3327928A1 (de) * 1983-08-03 1985-02-21 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
CN1056618C (zh) * 1993-09-17 2000-09-20 诺沃挪第克公司 酰化的胰岛素和含有这种胰岛素的药物组合物
KR100419037B1 (ko) * 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität

Also Published As

Publication number Publication date
ES2260832T3 (es) 2006-11-01
HUP0000547A3 (en) 2002-11-28
AU6612098A (en) 1998-10-20
CA2283705A1 (fr) 1998-10-01
EP1005490B1 (fr) 2006-03-29
JP3764174B2 (ja) 2006-04-05
KR20000076419A (ko) 2000-12-26
BR9808285A (pt) 2000-05-16
EP1627642A2 (fr) 2006-02-22
ATE321783T1 (de) 2006-04-15
HUP0000547A2 (hu) 2000-08-28
NO994520D0 (no) 1999-09-17
JP2001506272A (ja) 2001-05-15
NO994520L (no) 1999-09-17
EP1627642A3 (fr) 2006-04-19
RU2198181C2 (ru) 2003-02-10
AU742591B2 (en) 2002-01-10
CN1259142A (zh) 2000-07-05
DE69834028D1 (de) 2006-05-18
WO1998042749A1 (fr) 1998-10-01
PL335777A1 (en) 2000-05-22
US20070292520A1 (en) 2007-12-20
DE69834028T2 (de) 2006-12-07
US20070093411A1 (en) 2007-04-26
EP1005490A1 (fr) 2000-06-07
US20090311326A9 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
IL131796A0 (en) Zinc free insulin crystals for use in pulmonary compositions
HU9602454D0 (en) Methods and compositions for pulmonary delivery of insulin
HK1025515A1 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
MTP1012B (en) New pharmacologically active compounds,methods for the preperation thereof and compositions containing the same
AU2568792A (en) Benzanilide derivatives as 5-ht1d antagonists
AU2145688A (en) Improvements in or relating to vulcanizable compositions
NZ241385A (en) N-pyrimidinyl, -triazolyl and -triazinyl-n'-phenylsulphonyl urea and -thiourea derivatives; intermediates in the preparation thereof and herbicidal compositions
IL88503A0 (en) 2,2-difluorocyclopropylethane derivatives and insecticidal and acaricidal compositions containing the same
AU8771291A (en) Double-ended reversible box wrench with 7-1/2 degree swing clearance
AU627941B2 (en) Stabilized pergolide compositions
ZA923169B (en) Therapeutic compositions based on 1,2-dithiole-3-thione derivatives
IL99501A0 (en) Interleukin 9 receptors,methods for the use thereof and pharmaceutical compositions containing the same
PH25554A (en) Non-staling gum composition with improved wrappability
HUP0102609A3 (en) N-phenyl-n'-phenylpropylpiperazine derivatives and process for the preparation thereof, and pharmaceutical compositions containing them
HUT41738A (en) Herbicidal compositions comprising "1-aryl-4-cyano-5-halogen-pyrazoles and process for preparing the compounds
AU8817791A (en) Stabilised polyketone composition
SG59910A1 (en) Rare earth oxysulphide composition a process for the preparation thereof and use thereof as a luninophore
IL94057A0 (en) 5-substituted 3-arylisoxazole derivatives and insecticidal compositions containing the same
AU3005589A (en) N-(lower alkyl)-2-(3'-ureidobenzyl)-pyrrolidines
AU2857589A (en) Biocidal 4,5-dichloro-1,2-dithiol-3-one composition
AU4398489A (en) New composition for dynamico-functional impressions
EP0385960A3 (fr) Fourrage minéral mélangé et son procédé de fabrication
AU553330B2 (en) Oral antidiabetic composition comprising 5-substituted- oxazolidine-2,4.-dione and hypoglycemic sulfonylureas
EP0437416A3 (en) Compositions containing a 2,2',2"-nitrilotriethanol-cyclometallate
AU8433898A (en) Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for increasing insulin sensitivity